pancreatic cancer glutathione enhancement Increased glucose availability sensitizes to chemotherapy Thiostrepton induces ferroptosis in pancreatic

this strategy is mechanistically synergistic with immune checkpoint inhibitors (such as anti-PD-1/PD-L1 therapy), and the deep integration of the two holds promise for pioneering a new generation of treatment paradigms

Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1 235000021240 caseins Nutrition 0.000 description 1 239000003054 catalyst Substances 0.000 description 1 238000006555 catalytic reaction Methods 0.000 description 1 239000003093 cationic surfactant Substances 0.000 description 1 SVURIXNDRWRAFU-OGMFBOKVSA-N cedrol Chemical compound C1[C@]23[C@H](C)CC[C@H]3C(C)(C)[C@@H]1[C@@](O)(C)CC2 SVURIXNDRWRAFU-OGMFBOKVSA-N 0.000 description 1 229940026455 cedrol Drugs 0.000 description 1 PCROEXHGMUJCDB-UHFFFAOYSA-N cedrol Natural products CC1CCC2C(C)(C)C3CC(C)(O)CC12C3 PCROEXHGMUJCDB-UHFFFAOYSA-N 0.000 description 1 230000025084 cell cycle arrest Effects 0.000 description 1 230000036755 cellular response Effects 0.000 description 1 229940106157 cellulase Drugs 0.000 description 1 229940059958 centella asiatica extract Drugs 0.000 description 1 229940073669 ceteareth 20 Drugs 0.000 description 1 229940056318 ceteth-20 Drugs 0.000 description 1 229940049297 cetyl acetate Drugs 0.000 description 1 229940085262 cetyl dimethicone Drugs 0.000 description 1 229940074979 cetyl palmitate Drugs 0.000 description 1 230000008859 change Effects 0.000 description 1 150000005829 chemical entities Chemical class 0.000 description 1 238000001311 chemical methods and process Methods 0.000 description 1 238000007385 chemical modification Methods 0.000 description 1 239000007810 chemical reaction solvent Substances 0.000 description 1 RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1 229960001091 chenodeoxycholic acid Drugs 0.000 description 1 238000005660 chlorination reaction Methods 0.000 description 1 229940074393 chlorogenic acid Drugs 0.000 description 1 CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1 235000001368 chlorogenic acid Nutrition 0.000 description 1 FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1 150000001840 cholesterol esters Chemical class 0.000 description 1 150000001841 cholesterols Chemical class 0.000 description 1 229940072104 cholesteryl hydroxystearate Drugs 0.000 description 1 235000019416 cholic acid Nutrition 0.000 description 1 BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1 229960002471 cholic acid Drugs 0.000 description 1 KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1 229940059329 chondroitin sulfate Drugs 0.000 description 1 238000004587 chromatography analysis Methods 0.000 description 1 229940114081 cinnamate Drugs 0.000 description 1 235000017803 cinnamon Nutrition 0.000 description 1 229960001063 cinoxate Drugs 0.000 description 1 BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1 239000001926 citrus aurantium l

We next hypothesized that NADP oxidation during hypoxia may be due to NADPH consumption by the anti-oxidant machinery which is not matched by the rate of re-supply due to limitations in flux through central metabolism

JCI Insight 5 (2020)